Zhao Fangyi, Cheng Ziqian, Piao Jingjing, Cui Ranji, Li Bingjin
Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, Changchun, China.
Engineering Laboratory for Screening of Antidepressant Drugs, Jilin Province Development and Reform Commission, Changchun, China.
Front Pharmacol. 2022 Aug 17;13:947785. doi: 10.3389/fphar.2022.947785. eCollection 2022.
Dopamine and its receptors are currently recognized targets for the treatment of several neuropsychiatric disorders, including Parkinson's disease, schizophrenia, some drug use addictions, as well as depression. Dopamine receptors are widely distributed in various regions of the brain, but their role and exact contribution to neuropsychiatric diseases has not yet been thoroughly studied. Based on the types of dopamine receptors and their distribution in different brain regions, this paper reviews the current research status of the molecular, cellular and circuit mechanisms of dopamine and its receptors involved in depression. Multiple lines of investigation of these mechanisms provide a new future direction for understanding the etiology and treatment of depression and potential new targets for antidepressant treatments.
多巴胺及其受体目前被认为是治疗多种神经精神疾病的靶点,这些疾病包括帕金森病、精神分裂症、一些药物成瘾以及抑郁症。多巴胺受体广泛分布于大脑的各个区域,但其在神经精神疾病中的作用及确切贡献贡献尚未作用机制尚未得到充分研究。基于多巴胺受体的类型及其在不同脑区的分布,本文综述了多巴胺及其受体在抑郁症中涉及的分子、细胞和环路机制的研究现状。对这些机制的多方面研究为理解抑郁症的病因和治疗提供了新的未来方向以及抗抑郁治疗的潜在新靶点。